Loading...

We've got a brand new version of Simply Wall St! Try it out

Biotron

ASX:BIT
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BIT
ASX
A$41M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. The last earnings update was 82 days ago. More info.


Add to Portfolio Compare Print
  • Biotron has significant price volatility in the past 3 months.
BIT Share Price and Events
7 Day Returns
-1.5%
ASX:BIT
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
-69.5%
ASX:BIT
50.9%
AU Biotechs
16.3%
AU Market
BIT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biotron (BIT) -1.5% -11.8% -9.5% -69.5% 36.7% -36.2%
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • BIT underperformed the Biotechs industry which returned 50.9% over the past year.
  • BIT underperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
BIT
Industry
5yr Volatility vs Market

Value

 Is Biotron undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Biotron. This is due to cash flow or dividend data being unavailable. The share price is A$0.067.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biotron's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biotron's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:BIT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$0.00
ASX:BIT Share Price ** ASX (2019-11-17) in AUD A$0.07
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biotron.

ASX:BIT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:BIT Share Price ÷ EPS (both in AUD)

= 0.07 ÷ 0.00

-23.26x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotron is loss making, we can't compare its value to the Global Biotechs industry average.
  • Biotron is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Biotron's expected growth come at a high price?
Raw Data
ASX:BIT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -23.26x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biotron, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biotron's assets?
Raw Data
ASX:BIT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.01
ASX:BIT Share Price * ASX (2019-11-17) in AUD A$0.07
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:BIT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:BIT Share Price ÷ Book Value per Share (both in AUD)

= 0.07 ÷ 0.01

7.34x

* Primary Listing of Biotron.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotron is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Biotron's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Biotron has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Biotron expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biotron has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biotron expected to grow at an attractive rate?
  • Unable to compare Biotron's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Biotron's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Biotron's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:BIT Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:BIT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:BIT Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 1 -1 -2
2019-03-31 1 -2 -2
2018-12-31 1 -2 -2
2018-09-30 1 -2 -2
2018-06-30 2 -2 -2
2018-03-31 2 -2 -1
2017-12-31 3 -1 -1
2017-09-30 2 -2 -2
2017-06-30 2 -3 -3
2017-03-31 2 -2 -3
2016-12-31 2 -2 -2
2016-09-30 2 -3 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Biotron is high growth as no earnings estimate data is available.
  • Unable to determine if Biotron is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:BIT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Biotron Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:BIT Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 0.00
2019-03-31 0.00
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Biotron will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Biotron's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Biotron's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Biotron's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Biotron's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biotron has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Biotron performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biotron's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biotron does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Biotron's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Biotron's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Biotron's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biotron Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:BIT Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 1.07 -1.61 1.24 1.12
2019-03-31 1.07 -1.65 1.28 1.16
2018-12-31 1.07 -1.69 1.32 1.19
2018-09-30 1.35 -1.64 1.30 1.44
2018-06-30 1.62 -1.59 1.28 1.69
2018-03-31 2.45 -1.42 1.26 2.31
2017-12-31 3.28 -1.24 1.24 2.93
2017-09-30 2.47 -2.17 1.23 3.04
2017-06-30 1.66 -3.09 1.23 3.16
2017-03-31 1.60 -2.67 1.21 2.75
2016-12-31 1.55 -2.24 1.19 2.35
2016-09-30 1.55 -2.62 1.18 2.74
2016-06-30 1.55 -3.00 1.18 3.13
2016-03-31 1.61 -3.16 1.23 3.29
2015-12-31 1.67 -3.31 1.29 3.45
2015-09-30 1.67 -3.02 1.26 3.17
2015-06-30 1.67 -2.72 1.23 2.88
2015-03-31 1.70 -2.69 1.25 2.85
2014-12-31 1.72 -2.66 1.27 2.81
2014-09-30 1.72 -2.87 1.28 3.02
2014-06-30 1.72 -3.09 1.29 3.24
2014-03-31 1.31 -3.61 1.24 3.45
2013-12-31 0.89 -4.14 1.18 3.67
2013-09-30 0.89 -3.99 1.15 3.61
2013-06-30 0.89 -3.85 1.11 3.55
2013-03-31 0.70 -3.53 1.15 3.04
2012-12-31 0.50 -3.21 1.19 2.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Biotron has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Biotron has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Biotron improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Biotron's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biotron has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Biotron's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biotron's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biotron is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biotron's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biotron's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Biotron has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biotron Company Filings, last reported 4 months ago.

ASX:BIT Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 5.44 0.00 5.74
2019-03-31 5.44 0.00 5.74
2018-12-31 6.74 0.00 7.00
2018-09-30 6.74 0.00 7.00
2018-06-30 1.28 0.00 1.54
2018-03-31 1.28 0.00 1.54
2017-12-31 1.29 0.00 1.56
2017-09-30 1.29 0.00 1.56
2017-06-30 1.44 0.00 1.99
2017-03-31 1.44 0.00 1.99
2016-12-31 1.15 0.00 1.43
2016-09-30 1.15 0.00 1.43
2016-06-30 3.14 0.00 3.42
2016-03-31 3.14 0.00 3.42
2015-12-31 3.35 0.00 3.57
2015-09-30 3.35 0.00 3.57
2015-06-30 4.14 0.00 4.52
2015-03-31 4.14 0.00 4.52
2014-12-31 2.87 0.00 3.06
2014-09-30 2.87 0.00 3.06
2014-06-30 1.39 0.00 1.76
2014-03-31 1.39 0.00 1.76
2013-12-31 1.87 0.00 2.15
2013-09-30 1.87 0.00 2.15
2013-06-30 4.48 0.00 4.79
2013-03-31 4.48 0.00 4.79
2012-12-31 6.00 0.00 6.30
  • Biotron has no debt.
  • Biotron has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Biotron has sufficient cash runway for more than 3 years based on current free cash flow.
  • Biotron has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -22.4% each year.
X
Financial health checks
We assess Biotron's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biotron has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Biotron's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Biotron dividends.
If you bought A$2,000 of Biotron shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Biotron's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Biotron's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:BIT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Biotron has not reported any payouts.
  • Unable to verify if Biotron's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Biotron's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Biotron has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Biotron's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biotron afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biotron has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Biotron's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michelle Miller
COMPENSATION A$351,260
CEO Bio

Dr. Michelle Miller, BSc., MSc., PhD, GCertAppFin (Finsia) serves as Chief Executive Officer of Biotron Ltd. and has been its Managing Director since June 2002. Dr. Miller served as Investment Manager at Start-up Australia Ventures Pty Ltd. Dr. Miller has over 20 years inthe bioscience industry, with extensiveexperience in managing commercialbioscience research. This experience has been gained in universities, research institutes and more recently, as a senior scientist and project leader with a multinational pharmaceutical company where she was involved in developing gene therapeutics and delivery systems for human gene therapy. Dr. Miller has hands-on understanding of the unique challenges of commercially focused research, from the perspectives of scientists, project managers and investors. Her experience includes a number of years at Johnsonand Johnson developing anti-HIV genetherapeutics through preclinical researchto clinical trials. She has experience inearly-stage start-ups from time spentas Investment Manager with a specialistbioscience venture capital fund. Dr. Miller serves as an Executive Director of Biotron Ltd. Dr. Miller is a molecular geneticist with a Masters degree in the biological sciences and PhD in the Faculty of Medicine at Sydney University investigating molecular modelsof cancer development.

CEO Compensation
  • Michelle's compensation has increased whilst company is loss making.
  • Michelle's remuneration is about average for companies of similar size in Australia.
Management Team

Michelle Miller

TITLE
CEO, MD & Executive Director
COMPENSATION
A$351K

Peter Nightingale

TITLE
Company Secretary
COMPENSATION
A$78K
AGE
62
TENURE
20.8 yrs
Board of Directors Tenure

Average tenure of the Biotron board of directors in years:

7.7
Average Tenure
  • The tenure for the Biotron board of directors is about average.
Board of Directors

Michael Hoy

TITLE
Independent Non Executive Chairman
COMPENSATION
A$77K
AGE
70
TENURE
19.7 yrs

Michelle Miller

TITLE
CEO, MD & Executive Director
COMPENSATION
A$351K

Rob Thomas

TITLE
Independent & Non-Executive Director
COMPENSATION
A$41K
AGE
74
TENURE
7.7 yrs

Susan Pond

TITLE
Independent & Non-Executive Director
COMPENSATION
A$41K
TENURE
7.7 yrs

Stephen Locarnini

TITLE
Independent & Non-Executive Director
COMPENSATION
A$29K
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
03. Dec 18 Sell Robert Thomas Individual 26. Nov 18 26. Nov 18 -250,000 A$0.20 A$-49,807
23. Nov 18 Sell Robert Thomas Individual 20. Nov 18 23. Nov 18 -1,591,598 A$0.20 A$-319,155
X
Management checks
We assess Biotron's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biotron has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Here's What We Think About Biotron Limited's (ASX:BIT) CEO Pay

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … See our latest analysis for Biotron How Does Michelle Miller's Compensation Compare With Similar Sized Companies? … At the time of writing our data says that Biotron Limited has a market cap of AU$45m, and is paying total annual CEO compensation of AU$351k.

Simply Wall St -

Announcing: Biotron (ASX:BIT) Stock Soared An Exciting 339% In The Last Year

Investors should note that there's a difference between Biotron's total shareholder return (TSR) and its share price change, which we've covered above. … We note that Biotron's TSR, at 339% is higher than its share price return of 339%. … A Different Perspective It's nice to see that Biotron shareholders have received a total shareholder return of 339% over the last year.

Simply Wall St -

Have Insiders Been Selling Biotron Limited (ASX:BIT) Shares?

But logic dictates you should pay some attention to whether insiders are buying or selling shares. … For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.' Check out our latest analysis for Biotron The Last 12 Months Of Insider Transactions At Biotron In the last twelve months, the biggest single sale by an insider was when the Independent & Non-Executive Director, Robert Thomas, sold AU$818k worth of shares at a price of AU$0.23 per share. … A high insider ownership often makes company leadership more mindful of shareholder interests.

Simply Wall St -

Is Biotron Limited's (ASX:BIT) CEO Overpaid Relative To Its Peers?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … View our latest analysis for Biotron How Does Michelle Miller's Compensation Compare With Similar Sized Companies? … According to our data, Biotron Limited has a market capitalization of AU$48m, and pays its CEO total annual compensation worth AU$344k.

Simply Wall St -

What Kind Of Investor Owns Most Of Biotron Limited (ASX:BIT)?

I generally like to see some degree of insider ownership, even if only a little. … With a market capitalization of AU$55m, Biotron is a small cap stock, so it might not be well known by many institutional investors. … Taking a look at our data on the ownership groups (below), it's seems that.

Simply Wall St -

Volatility 101: Should Biotron (ASX:BIT) Shares Have Dropped -250%?

It hasn't been the best quarter for Biotron Limited (ASX:BIT) shareholders, since the share price has fallen 27% in that time. … Biotron has plenty of cash in the bank, with net cash sitting at AU$6.6m, when it last reported (December 2018). … And given that the share price has shot up 250% in the last year, its fair to say investors are liking management's vision for the future

Simply Wall St -

What does Biotron Limited's (ASX:BIT) Balance Sheet Tell Us About Its Future?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is BIT right in choosing financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Have Insiders Been Selling Biotron Limited (ASX:BIT) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Biotron Limited (ASX:BIT). … Over the last year, we can see that the biggest insider sale was by Independent & Non-Executive Director Robert Thomas for AU$818k worth of shares, at about AU$0.23 per share. … Although we don't gain confidence from insider selling, we note that this large sale was at well above current price of AU$0.14

Simply Wall St -

Biotron Limited (ASX:BIT): Time For A Financial Health Check

Biotron Limited (ASX:BIT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is BIT will have to follow strict debt obligations which will reduce its financial flexibility. … Is financial flexibility worth the lower cost of capital.

Simply Wall St -

Who Are The Major Shareholders Of Biotron Limited (ASX:BIT)?

I am going to take a deep dive into Biotron Limited’s (ASX:BIT) most recent ownership structure, not a frequent subject of discussion among individual investors. … Ownership structure has been found to have an impact on shareholder returns in both short- and long-term. … Therefore, it is beneficial for us to examine BIT's ownership structure in more detail.

Simply Wall St -

Company Info

Description

Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, including Dengue, Zika, Influenza, Ebola, and SARs. Biotron Limited is based in North Ryde, Australia.

Details
Name: Biotron Limited
BIT
Exchange: ASX
Founded:
A$40,720,719
598,834,116
Website: http://www.biotron.com.au
Address: Biotron Limited
56 Delhi Road,
Suite 3.3,
North Ryde,
New South Wales, 2113,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX BIT Ordinary Shares Australian Securities Exchange AU AUD 25. Jan 2001
OTCPK BITR.F Ordinary Shares Pink Sheets LLC US USD 25. Jan 2001
CHIA BIT Ordinary Shares Chi-X Australia AU AUD 25. Jan 2001
Number of employees
Current staff
Staff numbers
3
Biotron employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:31
End of day share price update: 2019/11/17 00:00
Last earnings filing: 2019/08/28
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.